Crystallization and polymorphism of Flubendazole and other ill-characterized drugs

• Grant number: 15/05685-7
• Support Opportunities: Regular Research Grants
• Duration: January 01, 2016 - June 30, 2018
• Field of knowledge: Health Sciences - Pharmacy - Medicines Analysis and Control
• Principal Investigator: Gabriel Lima Barros de Araujo
• Grantee: Gabriel Lima Barros de Araujo
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Carlos de Oliveira Paiva Santos ; Fabio Furlan Ferreira ; Juliana Alves Pereira Sato ; Rondes Ferreira da Silva Torin ; Selma Gutierrez Antonio

Abstract

Polymorphism, the ability of a substance to crystallize in more than one lattice arrangement, is currently a major concern for the pharmaceutical industry. Albeit the molecule does not change, different packing architectures can lead to significant differences in physicochemical properties that play a key role in the performance of medicines. Thus, in recent years there has been a significant increase in investments to uncover new polymorphs and other crystal forms (e.g. solvates, co-crystals) of existing active ingredients (APIs), aiming at the improvement of their safe use and therapeutic efficacy. This project falls within this scope and focuses on: (i) preparation of polymorphs, solvates, or co-crystals of APIs; (ii) their characterization in terms of structure and thermodynamic stability; (iii) their in silico evaluation in terms of biopharmaceutical performance.The main target molecule will be the antihelmintic and potential antitumor agent flubendazole, for which, to the best of our knowledge, no polymorphism studies have been reported. This represents a significant drawback for the safe use, manufacture and quality control of pharmaceutical formulations based on this active principle. (AU)

Scientific publications

(5)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE ARAUJO, GABRIEL L. B.; FERREIRA, FABIO FURLAN; BERNARDES, CARLOS E. S.; SATO, JULIANA A. P.; GIL, OTAVIO M.; DE FARIA, DALVA L. A.; LOEBENBERG, RAIMAR; BYRN, STEPHEN R.; GHISLENI, DANIELA D. M.; BOU-CHACRA, NADIA A.; et al. A New Thermodynamically Favored Flubendazole/Maleic Acid Binary Crystal Form: Structure, Energetics, and in Silico PBPK Model-Based Investigation. Crystal Growth & Design, v. 18, n. 4, p. 2377-2386, APR 2018. (15/05685-7, 15/26233-7)

DE ARAUJO, GABRIEL L. B.; ZELLER, MATTHIAS; SMITH, DANIEL; NIE, HAICHEN; BYRN, STEPHEN R.. Unexpected Single Crystal Growth Induced by a Wire and New Crystalline Structures of Lapatinib. Crystal Growth & Design, v. 16, n. 10, p. 6122-6130, OCT 2016. (15/15456-5, 15/05685-7)

ZELLER, MATTHIAS; BARROS DE ARAUJO, GABRIEL LIMA; PARKER, TREV; RAI, AMRINDER SINGH; BYRN, STEPHEN R.. A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, v. 73, n. 3, p. 417+, MAR 2017. (15/05685-7, 15/15456-5)

DE ARAUJO, GABRIEL L. B.; BENMORE, CHRIS J.; BYRN, STEPHEN R.. Local Structure of Ion Pair Interaction in Lapatinib Amorphous Dispersions characterized by Synchrotron X-Ray diffraction and Pair Distribution Function Analysis. SCIENTIFIC REPORTS, v. 7, APR 11 2017. (15/05685-7, 15/15456-5)

REPIN, ILIA ALEKSEEVICH; LOEBENBERG, RAIMAR; DIBELLA, JOHN; CONCEICAO, ANTONIO C. L.; MINAS DA PIEDADE, MANUEL E.; FERRAZ, HUMBERTO G.; ISSA, MICHELE G.; BOU-CHACRA, NADIA A.; ERMIDA, CATHARINE F. M.; DE ARAUJO, GABRIEL L. B.. Exploratory Study on Lercanidipine Hydrochloride Polymorphism: pH-Dependent Solubility Behavior and Simulation of its Impact on Pharmacokinetics. AAPS PHARMSCITECH, v. 22, n. 2, FEB 21 2021. (15/05685-7)